Wednesday 21 November 2018 ,
Wednesday 21 November 2018 ,
Latest News
  • Bangladesh excludes Hindu Rohingya families from repatriation: Myanmar
  • 4 killed in Chicago hospital shooting
  • Int'l support must for Bangladesh to ensure inclusive edu for Rohingyas: Unesco
  • 3 killed in Cox’s Bazar ‘gunfight
10 September, 2018 00:00 00 AM / LAST MODIFIED: 10 September, 2018 01:15:26 AM

FDA approves Xerava

drugs.com
FDA approves Xerava

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently announced that the U.S. Food and Drug Administration (FDA) has granted approval of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). In clinical trials, Xerava was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem.

Xerava is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

“The approval of Xerava is an extraordinary achievement, one for which we thank the patients who have participated in our clinical studies, study investigators and physicians as well as our dedicated employees,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We are thrilled to have received FDA approval, and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe all within the same quarter. Each milestone is a significant accomplishment on its own and achieving both underscores the potential for Tetraphase and the medical need for Xerava.”

Dr. Barie added, “Eravacycline also has a favorable safety profile as observed in clinical trials, and no dose adjustment is required when given to patients with renal impairment, which is advantageous for seriously ill patients who may have impaired kidney function. Additionally, the drug may be given safely to patients who are allergic to penicillin. This new and novel treatment may be of great benefit to patients with complicated intra-abdominal infections.”

Intra-abdominal infection (IAI) is a common problem in clinical practice and comprises a wide variety of disease processes. IAI is classified as uncomplicated or complicated based on the extent of the infection. Complicated intra-abdominal infections (cIAI) extend beyond the source organ into the peritoneal space (the space between the two membranes that separate the organs in the abdominal cavity from the abdominal wall) as a result of perforation or other damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. Different bacterial pathogens are responsible for cIAI, including Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria.

Early detection, containment and appropriate antimicrobial treatment are essential to the successful treatment of IAI. This is even more critical with increasing rates of infections caused by drug-resistant bacteria, which limit the effectiveness of currently available antibiotics.

Important safety information

Xerava is a tetracycline class antibacterial indicated for the treatment of complicated intra abdominal infections in patients 18 years of age and older.

Xerava is not indicated for the treatment of complicated urinary tract infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Xerava is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with Xerava.

The use of Xerava during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of Xerava during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea, and vomiting.

Xerava is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with Xerava. Discontinue Xerava if any of these adverse reactions are suspected.

About Xerava

Xerava (eravacycline for injection) is a novel, fully-synthetic fluorocycline, FDA-approved antibiotic for the treatment of cIAI. Xerava has demonstrated potent activity against MDR pathogens.

Xerava was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, Xerava achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.

 

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

World Lung Cancer Day has been observed this year with the theme ‘Honour, Unite, Inspire’. Lung cancer continues to be one of the most common…
What is lung cancer?

What is lung cancer?

Lung cancer originates from tissues of the lung, usually from cells lining the air passages. The two main types are small cell lung cancer (SCLC) and…
Understanding lung cancer - the basics

Understanding lung cancer - the basics

Although lung cancer is the leading cause of cancer death in the U.S. in both men and women, it is also one of the most preventable kinds of cancer. At…
Changing paradigm in management of lung cancer

Changing paradigm in management of lung cancer

Lung cancer in Asia is a major public health problem as it contributes to high morbidity and mortality. The incidence of smoking continues to rise in…
The lifestyle changes you can make today to reduce your lung cancer risk

The lifestyle changes you can make today to reduce your lung cancer risk

You already know that lung cancer can develop in someone who's never smoked a cigarette and that the disease is linked to lifestyle risk factors,…
Perimenopause: symptoms, signs and treatment

Perimenopause: symptoms, signs and treatment

Claire Chamberlain   Struggling with irregular periods, extreme bleeding, vaginal dryness, loss of libido or migraine headaches? All of these symptoms…
Your heart hates air pollution portable filters could help

Your heart hates air pollution portable filters could help

Haley Otman Microscopic particles floating in the air we breathe come from sources such as fossil fuel combustion, fires, cigarettes and vehicles. Known…
A complicated case of incomplete therapeutic abortion managed by homeopathy

A complicated case of incomplete therapeutic abortion managed by homeopathy

Patients undergoing induced abortions in hospitals and clinics at times die of profuse haemorrhage. Incidentally I had the opportunity to treat such a…
Acupuncture treatment for infertility & improving ART (IVF) success rate

Acupuncture treatment for infertility & improving ART (IVF) success rate

Infertility means that a couple is not sterile but for some reason has not been able to conceive a child despite of frequent unprotected sex for at least…
Fat-clogged cells explain why obesity can cause cancer

Fat-clogged cells explain why obesity can cause cancer

A new discovery could explain why obese people are more likely to develop cancer, scientists say. A type of cell the body uses to destroy cancerous tissue…
World Diabetes Day Celebration: 150 rallies organised across the country

World Diabetes Day Celebration: 150 rallies organised across the country

World Diabetes Day was observed in the country to raise awareness and promote early diagnosis to prevent this non-communicable disease. To mark the day,…
AstraZeneca's diabetes drug curbs heart failure, kidney risks

AstraZeneca's diabetes drug curbs heart failure, kidney risks

Ben Hirschler The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure…
FDA approves Lorbrena (lorlatinib) for previously-treated ALK-positive metastatic non-small cell lung cancer

FDA approves Lorbrena (lorlatinib) for previously-treated ALK-positive metastatic non-small cell lung cancer

Recently, announced that the U.S. Food and Drug Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting